GlaucoT develops non-invasive, neuroprotective wearable treatment device for the glaucoma disease that is the most common cause of irreversible blindness in the world. GlaucoT proposes a novel neuroprotective treatment method for Glaucoma patients.
GlaucoT develops a new treatment method with a neuroprotective, noninvasive, drug-free wearable medical device. GlaucoT proposes a smart wearable device designed for gamma rhythm training in order to reduce neuroinflammation and to reduce the pressure on the optical nerve. GlaucoT wearable device consists of smart glasses that provide these novel treatments together without requiring any medicine or any type of surgical operation. Patients will wear the smart glasses one hour per day at the home comfort. A smart application will keep track of the treatment and give instructions to the users. GlaucoT’s unique treatment method removes toxic proteins (amyloid beta, tau protein) in the visual cortex. Glaucoma patients will get an efficient treatment with GlaucoT. So they will not be worried for their entire lives of becoming blind. Glaucoma is known as an eye disease; however, it is a ‘brain’ and ‘eye’ disease. For this reason, the current treatment methods that target only eye cannot provide a complete solution to this problem.
Since Glaucoma patients do not currently have an effective treatment method which takes care of *both* i) neurodegeneration and ii) intraocular pressure, they are at high risks of becoming blind in the latter stages of the disease. GlaucoT creates a new wearable glaucoma treatment device for the global glaucoma treatment market. GlaucoT will get a strong position in the global market with its unique features. New wearable medical technologies will be key platforms by collecting data not only from hospitals and medical centers but also from patients’ homes. New wearable technologies will have significant advantages, optimizing the treatment of patients, and preventing the disease from causing complications.
Recent supporting articles mention that flickering light treatment stops retinal aging [1] and removes the toxic proteins in the brain that are the products of the neurodegenerative diseases [2].
We have started our clinical trials in Turkey in two hospitals in Feb 2022 (Manisa Celal Bayar Univ and Ege Univ). Our first results show improvements on the retina layer of the patients. This has never been observed with the traditional treatments. For details: (ClinicalTrials.gov Identifier: NCT05253534)
We are really excited to be selected for the EIT Health 2022 Catapult Semifinal. This programme recognises and awards the very best business concepts, fast-tracking start-ups to become part of the EIT Health Community of world-leading companies.
[1] – https://pubmed.ncbi.nlm.nih.gov/34698960/
[2] – https://www.nature.com/articles/nature20587